Discovery of the first N -hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3324-3341

  Li, Xiaoyang ^a   Inks, Elizabeth S ^b   Li, Xiaoguang ^a   Hou, Jinning ^a   Chou, C James ^b   Zhang, Jian ^a   Jiang, Yuqi ^a   Zhang, Yingjie ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; 3 [4 [3 (1H INDOL 3 YL) 2 [[(4 METHYLPHENYLSULFONAMIDO)PROPOXY]PHENYL] N HYDROXYACRYLAMIDE; 3 [4 [3 (1H INDOL 3 YL)]] 2 [[(2 PHENYLACETAMIDO)PROPOXY]PHENYL] N HYDROXYACRYLAMIDE; 4 CHLORO N [1 [3 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]]3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; 4 CHLORO N [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; 4 FLOURO N [1 [3 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; 4 FLUORO N [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; 4 METHOXY N [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; N [1 [3 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; N [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]BENZAMIDE; PANOBINOSTAT; TERT BUTY 3 HYDROXY [1 [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]]] 3 [[[(1H INDOL 3 YL)PROPAN 2 YL]AMINO] 1 OXOPROPAN 2 YL]CARBAMATE; TERT BUTYL 4 CHLOROBENZYL[1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]CARBAMATE; TERT BUTYL 4 FLUOROBENZYL[1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]CARBAMATE; TERT BUTYL [1 [1 [4 3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXYL]] 3 [[(1H INDOL 3 YL)PROPAN 2 YL]AMINO] 4 (METHYLTHIO) 1 OXOBUTAN 2 YLCARBAMATE; TERT BUTYL [3 HYDROXY 1 [1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]]] 3 [[[(1H INDOL 3 YL)PROPAN 2 YL]AMINO] 1 OXOBUTAN 2 YL]CARBAMATE; TERT BUTYLBENZYL[1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]CARBAMATE; TERT BUTYL[1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]] 3 [(1H INDOL 3 YL)PROPAN 2 YL]CARBAMATE; TERT BUTYL[2 [[1 [4 [3 (HYDROXYAMINO) 3 OXOPROP 1 EN 1 YL]PHENOXY]]]] 3 [[[(1H INDOL 3 YL)PROPAN 2 YL]AMINO] 2 OXOETHYL]CARBAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; MITSUNOBU REACTION; MOLECULAR DOCKING; MULTIPLE CANCER; NONHUMAN; RAT; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; FEMALE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899565467     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401877m     Document Type: Article

References (32)

1. Herman, J. G.; Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation N. Engl. J. Med. 2003, 349, 2042-2054
2. Zhang, Y.; Fang, H.; Jiao, J.; Xu, W. The structure and function of histone deacetylases: the target for anti-cancer therapy Curr. Med. Chem. 2008, 15, 2840-2849
3. Kristensen, L. S.; Nielsen, H. M.; Hansen, L. L. Epigenetics and cancer treatment Eur. J. Pharmacol. 2009, 625, 131-142
4. Gregoretti, I.; Lee, Y.-M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 2004, 338, 17-31
5. Stünkel, W.; Campbell, R. M. Sirtuin 1 (SIRT1) the misunderstood HDAC J. Biomol. Screening 2011, 16, 1153-1169
6. Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeir, R.; Jenuwein, T. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression EMBO J. 2002, 21, 2672-2681
7. Simboeck, E.; Di Croce, L. HDAC1, a novel marker for benign teratomas EMBO J. 2010, 29, 3893-3895
8. Pilarsky, C.; Wenzig, M.; Specht, T.; Saeger, H. D.; Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data Neoplasia 2004, 6, 744-750
9. Karagianni, P.; Wong, J. HDAC3: taking the SMRT-N-CoRrect road to repression Oncogene 2007, 26, 5439-5449
10. Wilson, A. J.; Byun, D.-S.; Popova, N.; Murray, L. B.; L'Italien, K.; Sowa, Y.; Arango, D.; Velcich, A.; Augenlicht, L. H.; Mariadason, J. M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J. Biol. Chem. 2006, 281, 13548-13558
11. Godman, C. A.; Joshi, R.; Tierney, B. R.; Greenspan, E.; Rasmussen, T. P.; Wang, H.-W.; Shin, D.-G.; Rosenberg, D. W.; Giardina, C. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling Cancer Biol. Ther. 2008, 7, 1570-1580
12. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R.-Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA Biochem. Biophys. Res. Commun. 2003, 310, 529-536
13. Feng, L.; Pan, M.; Sun, J.; Lu, H.; Shen, Q.; Zhang, S.; Jiang, T.; Liu, L.; Jin, W.; Chen, Y. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells J. Mol. Med. 2013, 91, 49-58
14. Zhu, J.; Wan, H.; Xue, C.; Jiang, T.; Qian, C.; Zhang, Y. Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration Brain Res. 2013, 1520, 15-22
15. Fritzsche, F. R.; Weichert, W.; Röske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Scholman, K.; Denkert, C.; Dietel, M. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer BMC Cancer 2008, 8, 381
16. Yang, Z.; Zhou, L.; Wu, L.-M.; Xie, H.-Y.; Zhang, F.; Zheng, S.-S. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy Clin. Chem. Lab. Med. 2010, 48, 1785-1791
17. Van Damme, M.; Crompot, E.; Meuleman, N.; Mineur, P.; Bron, D.; Lagneaux, L.; Stamatopoulos, B. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance Epigenetics 2012, 7, 1403-1412
18. Moffat, D.; Patel, S.; Day, F.; Belfield, A.; Donald, A.; Rowlands, M.; Wibawa, J.; Brotherton, D.; Stimson, L.; Clark, V. J. Med. Chem. 2010, 53, 8663
19. Arts, J.; King, P.; Mariën, A.; Floren, W.; Beliën, A.; Janssen, L.; Pilatte, I.; Roux, B.; Decrane, L.; Gilissen, R. Clin. Cancer Res. 2009, 15, 6841
20. Bergman, J. A.; Woan, K.; Perez-Villarroel, P.; Villagra, A.; Sotomayor, E. M.; Kozikowski, A. P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth J. Med. Chem. 2012, 55, 9891-9899
21. Gupta, P. K.; Reid, R. C.; Liu, L.; Lucke, A. J.; Broomfield, S. A.; Andrews, M. R.; Sweet, M. J.; Fairlie, D. P. Inhibitors selective for HDAC6 in enzymes and cells Bioorg. Med. Chem. Lett. 2010, 20, 7067-7070
22. Bürli, R. W.; Luckhurst, C. A.; Aziz, O.; Matthews, K. L.; Yates, D.; Lyons, K. A.; Beconi, M.; McAllister, G.; Breccia, P.; Stott, A. J. Design, synthesis, and biological evaluation of potent and selective Class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease J. Med. Chem. 2013, 56, 9934-9954
23. Shi, B.; Xu, W. The development and potential clinical utility of biomarkers for HDAC inhibitors Drug Discovery Ther. 2013, 7, 129-136
24. Prince, H. M.; Bishton, M. J.; Harrison, S. J. Clinical studies of histone deacetylase inhibitors Clin. Cancer Res. 2009, 15, 3958-3969
25. Boumber, Y.; Younes, A.; Garcia-Manero, G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor Expert Opin. Invest. Drugs 2011, 20, 823-829
26. Moradei, O. M.; Mallais, T. C.; Frechette, S.; Paquin, I.; Tessier, P. E.; Leit, S. M.; Fournel, M.; Bonfils, C.; Trachy-Bourget, M.-C.; Liu, J. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity J. Med. Chem. 2007, 50, 5543-5546
27. Methot, J. L.; Chakravarty, P. K.; Chenard, M.; Close, J.; Cruz, J. C.; Dahlberg, W. K.; Fleming, J.; Hamblett, C. L.; Hamill, J. E.; Harrington, P. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1: 2) Bioorg. Med. Chem. Lett. 2008, 18, 973-978
28. Zhang, Y.; Yang, P.; Chou, C. J.; Liu, C.; Wang, X.; Xu, W. Development of N -hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap group ACS Med. Chem. Lett. 2013, 4, 235-238
29. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458
30. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J. 2003, 22, 1168-1179
31. Spencer, S. L.; Sorger, P. K. Measuring and modeling apoptosis in single cells Cell 2011, 144, 926-939
32. Teksin, Z. S.; Seo, P. R.; Polli, J. E. Comparison of drug permeabilities and BCS classification: Three lipid-component PAMPA system method versus Caco-2 monolayers AAPS J. 2010, 12, 238-241